Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q1 2019 · 10-Q
Revenue—
Net Income-$11.34M-$11.34MN/M vs Q1 2018 EPS Diluted-$0.42-$0.42N/M vs Q1 2018 Operating Income-$11,758,000N/M Operating Cash Flow-$8,696,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
Free Cash Flowderived-$9,031,000N/M ended Mar 31, 2019 · filed May 7, 2019 · 37 d after period end